DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Phase 1

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: ABT-354
Drug: Placebo

First Posted Date: 2013-07-25

Last Posted Date: 2013-12-11

Lead Sponsor: AbbVie

Target Recruit Count: 20

Registration Number: NCT01908010

Locations: 🇺🇸
Site Reference ID/Investigator# 106999, Miami, Florida, United States
🇺🇸
Site Reference ID/Investigator# 107000, Overland Park, Kansas, United States
🇺🇸
Site Reference ID/Investigator# 106998, Orlando, Florida, United States

A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery

Phase 2

Terminated

Conditions: Cardiothoracic Surgery
Vascular Surgery

Interventions: Drug: ABT-719
Drug: Placebo

First Posted Date: 2013-07-12

Last Posted Date: 2014-06-06

Lead Sponsor: AbbVie

Target Recruit Count: 56

Registration Number: NCT01897519

Locations: 🇺🇸
Site Reference ID/Investigator# 103356, Boston, Massachusetts, United States
🇺🇸
Site Reference ID/Investigator# 102020, Cleveland, Ohio, United States
🇺🇸
Site Reference ID/Investigator# 103355, Columbus, Ohio, United States

and more 20 locations

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Phase 2

Completed

Conditions: Cancer of the Blood and Bone Marrow
17p Deletion
Chronic Lymphocytic Leukemia

Interventions: Drug: ABT-199 (Safety Expansion Cohort)
Drug: ABT-199 (Main Cohort)

First Posted Date: 2013-06-28

Last Posted Date: 2021-12-16

Lead Sponsor: AbbVie

Target Recruit Count: 158

Registration Number: NCT01889186

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey /ID# 92513, New Brunswick, New Jersey, United States
🇺🇸
Hackensack Univ Med Ctr /ID# 92500, Hackensack, New Jersey, United States
🇦🇺
Peter MacCallum Cancer Ctr /ID# 91795, Melbourne, Victoria, Australia

and more 45 locations

Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of Life in Crohn's Disease

Completed

Conditions: Crohn's Disease

First Posted Date: 2013-05-23

Last Posted Date: 2017-06-16

Lead Sponsor: AbbVie

Target Recruit Count: 106

Registration Number: NCT01860846

Study Of Diabetic Nephropathy With Atrasentan

Phase 3

Terminated

Conditions: Diabetic Nephropathy

Interventions: Drug: Atrasentan
Drug: Placebo

First Posted Date: 2013-05-21

Last Posted Date: 2019-04-24

Lead Sponsor: AbbVie

Target Recruit Count: 5107

Registration Number: NCT01858532

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

Completed

Conditions: Cystic Fibrosis

First Posted Date: 2013-05-21

Last Posted Date: 2020-12-09

Lead Sponsor: AbbVie

Target Recruit Count: 1310

Registration Number: NCT01858519

Locations: 🇺🇸
Site Reference ID/Investigator# 116382, Anchorage, Alaska, United States
🇺🇸
Site Reference ID/Investigator# 116595, Long Beach, California, United States
🇺🇸
Site Reference ID/Investigator# 116441, Hartford, Connecticut, United States

and more 44 locations

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults

Phase 3

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ABT-450/r/ABT-267, ABT-333
Drug: Pegylated Interferon a-2a (PegINF)
Drug: Ribavirin
Drug: Telaprevir

First Posted Date: 2013-05-15

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie

Target Recruit Count: 148

Registration Number: NCT01854528

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

Phase 1

Completed

Conditions: BRCA Mutated
Oncology
BRCA Mutated Breast Cancer
High Grade Serous Ovarian Cancer

Interventions: Drug: Veliparib

First Posted Date: 2013-05-15

Last Posted Date: 2017-11-21

Lead Sponsor: AbbVie

Target Recruit Count: 71

Registration Number: NCT01853306

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

Phase 3

Completed

Conditions: Chronic Hepatitis C Infection

Interventions: Drug: ABT-450/r/ABT-267, ABT-333
Drug: Ribavirin
Drug: Telaprevir
Drug: Pegylated Interferon alpha 2-a (PegIFN)

First Posted Date: 2013-05-15

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie

Target Recruit Count: 311

Registration Number: NCT01854697

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: ABT-122
Biological: Placebo

First Posted Date: 2013-05-14

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 19

Registration Number: NCT01853033

Locations: 🇺🇸
Site Reference ID/Investigator# 118964, Duncansville, Pennsylvania, United States
🇺🇸
Site Reference ID/Investigator# 107115, Raleigh, North Carolina, United States
🇺🇸
Site Reference ID/Investigator# 100780, Dallas, Texas, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy